您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Deflazacort
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Deflazacort
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Deflazacort图片
CAS NO:14484-47-0
包装与价格:
包装价格(元)
10mM (in 1mL DMSO)电议
50mg电议

产品介绍
Deflazacort 是一种糖皮质激素,是一种无活性的前药,可迅速转化为活性代谢物 21-去乙酰地氟扎可特。
Cas No.14484-47-0
别名地夫可特
化学名2-((6aR,6bS,7S,8aS,8bS,11aR,12aS,12bS)-7-hydroxy-6a,8a,10-trimethyl-4-oxo-2,4,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-1H-naphtho[2',1':4,5]indeno[1,2-d]oxazol-8b-yl)-2-oxoethyl acetate
Canonical SMILESO=C(C([H])([H])OC(C([H])([H])[H])=O)[C@@]12N=C(C([H])([H])[H])O[C@]1([H])C([H])([H])[C@]([C@@](C([H])([H])C3([H])[H])([H])[C@@]4([H])[C@@](C([H])([H])[H])(C([H])=C5[H])C3=C([H])C5=O)([H])[C@]2(C([H])([H])[H])C([H])([H])[C@]4([H])O[H]
分子式C25H31NO6
分子量441.52
溶解度≥ 18.75mg/mL in DMSO
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Deflazacort is a glucocorticoid used as an anti-inflammatory and immunosuppressant.Target: Glucocorticoid ReceptorDeflazacort is an inactive prodrug which is converted rapidly to the active metabolite 21-desacetyldeflazacort. Maximum concentrations of 21-desacetyldeflazacort averaged 116 ng/ml and were observed after 1.3 h. The average area under the curve was 280 ng/ml.h, and the terminal half-life was 1.3 h. 21-Desacetyldeflazacort was cleared significantly faster than both methylprednisolone and prednisolone [1]. Two of 40 boys treated with deflazacort died at 13 and 18 years of age from cardiac failure. The treated boys were significantly shorter, did not have excessive weight gain and 22 of 40 had asymptomatic cataracts. Deflazacort has a very significant impact on health, quality of life and health care costs for boys with DMD and their families, and is associated with few side effects [2].

References:
[1]. Mollmann, H., et al., Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone. Pharmaceutical research, 1995. 12(7): p. 1096-1100.
[2]. Biggar, W., et al., Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscular Disorders, 2006. 16(4): p. 249-255.